DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
DETECT
Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD Under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners
1 other identifier
observational
3,732
1 country
180
Brief Summary
Prospective, multi-centre, non-interventional study to collect findings about the effects of LABA/LAMA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists) combination preparations on COPD (Chronic obstructive pulmonary disease) symptoms and quality of life under real conditions and to find out what types of patients are selected for this therapy by physicians.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2015
Typical duration for all trials
180 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 29, 2015
CompletedFirst Posted
Study publicly available on registry
September 17, 2015
CompletedStudy Start
First participant enrolled
September 24, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2017
CompletedDecember 11, 2018
December 1, 2018
2.3 years
July 29, 2015
December 10, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Lung function
Assessment of FEV1 (Forced Expiratory Volume), FVC (Forced Vital Capacity)
First visit (baseline)
Number of patients with concomitant diseases classified by diagnostic subgroups
First visit (baseline)
Number of patients receiving concomitant COPD (Chronic obstructive pulmonary disease) medication classified by therapeutic subgroups
First visit (baseline)
Number of patients with exacerbations within the previous 24 months
History of previous exacerbations that will be collected at first observational visit.
First visit (baseline)
Secondary Outcomes (7)
Change in well-being and quality of life
First visit (baseline) to end of observational period at 12 months
Effect on the severity of the shortness of breath
First visit (baseline) to end of observational period at 12 months
Change in the night-time and early-morning COPD symptoms
First visit (baseline) to end of observational period at 12 months
Lung function
First visit (baseline) to end of observational period at 12 months
Number of exacerbations by grade
First visit (baseline) to end of observational period at 12 months
- +2 more secondary outcomes
Study Arms (3)
Patients on Duaklir® Genuair®
Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
Patients on Ultibro® Breezhaler®
Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
Patients on Anoro®
Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
Eligibility Criteria
Patients who have been diagnosed with COPD (Chronic obstructive pulmonary disease), who have been changed over within the last 3 months to one of the 3 listed fixed-dose combinations (FDC) or for whom such a changeover is intended, and whose lung function parameters and CAT (COPD Assessment Test™) score from the time prior to the changeover are available (within the last 6 months) or are determined at the time of the 1st visit, if this is planned as part of the routine treatment.
You may qualify if:
- Female/male of at least 40 years of age
- Patient diagnosed with COPD
- Patient was changed over within the last 3 months to a fixed-dose combination (FDC) (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol), or there is already the intent to change the patient over to a fixed-dose combination (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol).
- Lung function parameters and CAT score from the time prior to the changeover to an FDC are on record (within the last 6 months in the case of patients who have already been changed over) or are determined at the 1st visit (in the case of patients who have not yet been changed over but for whom such a changeover is intended).
- Signed declaration of consent
You may not qualify if:
- The prescribing information for the fixed-dose combinations (Duaklir® Genuair®, Ulibtro® Breezhaler® or Anoro®) list contraindications for the patient.
- Patient is pregnant, plans to become pregnant, or is nursing during the therapy period.
- Patient suffers from hypersensitivity to one of the active ingredients of the fixed-dose combinations.
- Patient is participating in a clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (180)
Research Site
Aachen, D6570r00001, D6570R00001, Germany
Research Site
Aldenhofen, D6570r00001, D6570R00001, Germany
Research Site
Aldenhoven, D6570r00001, D6570R00001, Germany
Research Site
Alzey, D6570r00001, D6570R00001, Germany
Research Site
Ansbach, D6570r00001, D6570R00001, Germany
Research Site
Apolda, D6570r00001, D6570R00001, Germany
Research Site
Aschau, D6570r00001, D6570R00001, Germany
Research Site
Auerbach, D6570r00001, D6570R00001, Germany
Research Site
Augsburg, D6570r00001, D6570R00001, Germany
Research Site
Bad Fallingbostel, D6570r00001, D6570R00001, Germany
Research Site
Bad Hersfeld, D6570r00001, D6570R00001, Germany
Research Site
Bad Honnef, D6570r00001, D6570R00001, Germany
Research Site
Bad Lippspringe, D6570r00001, D6570R00001, Germany
Research Site
Bad Reichenhall, D6570r00001, D6570R00001, Germany
Research Site
Bad Sachsa, D6570r00001, D6570R00001, Germany
Research Site
Bad Windsheim, D6570r00001, D6570R00001, Germany
Research Site
Bad Wörishofen, D6570r00001, D6570R00001, Germany
Research Site
Bamberg, D6570r00001, D6570R00001, Germany
Research Site
Beelitz-Heilstätten, D6570r00001, D6570R00001, Germany
Research Site
Bergisch Gladbach, D6570r00001, D6570R00001, Germany
Research Site
Berlin, D6570r00001, D6570R00001, Germany
Research Site
Biberach, D6570r00001, D6570R00001, Germany
Research Site
Birkenwerder, D6570r00001, D6570R00001, Germany
Research Site
Bitterfeld-Wolfen, D6570r00001, D6570R00001, Germany
Research Site
Bochum, D6570r00001, D6570R00001, Germany
Research Site
Bonn, D6570r00001, D6570R00001, Germany
Research Site
Bottrop, D6570r00001, D6570R00001, Germany
Research Site
Böhlen, D6570r00001, D6570R00001, Germany
Research Site
Braunschweig, D6570r00001, D6570R00001, Germany
Research Site
Bruchsal, D6570r00001, D6570R00001, Germany
Research Site
Burghaslach, D6570r00001, D6570R00001, Germany
Research Site
Burgwedel, D6570r00001, D6570R00001, Germany
Research Site
Büchen, D6570r00001, D6570R00001, Germany
Research Site
Celle, D6570r00001, D6570R00001, Germany
Research Site
Chemnitz, D6570r00001, D6570R00001, Germany
Research Site
Cologne, D6570r00001, D6570R00001, Germany
Research Site
Cottbus, D6570r00001, D6570R00001, Germany
Research Site
Darmstadt, D6570r00001, D6570R00001, Germany
Research Site
Delitzsch, D6570r00001, D6570R00001, Germany
Research Site
Dessau, D6570r00001, D6570R00001, Germany
Research Site
Dorsten, D6570r00001, D6570R00001, Germany
Research Site
Dortmund, D6570r00001, D6570R00001, Germany
Research Site
Dresden, D6570r00001, D6570R00001, Germany
Research Site
Duisburg, D6570r00001, D6570R00001, Germany
Research Site
Düren, D6570r00001, D6570R00001, Germany
Research Site
Düsseldorf, D6570r00001, D6570R00001, Germany
Research Site
Eimsheim, D6570r00001, D6570R00001, Germany
Research Site
Ellerstadt, D6570r00001, D6570R00001, Germany
Research Site
Elsterwerda, D6570r00001, D6570R00001, Germany
Research Site
Elterlein, D6570r00001, D6570R00001, Germany
Research Site
Essen, D6570r00001, D6570R00001, Germany
Research Site
Euerbach-Obbach, D6570r00001, D6570R00001, Germany
Research Site
Euskirchen, D6570r00001, D6570R00001, Germany
Research Site
Flensburg, D6570r00001, D6570R00001, Germany
Research Site
Frankfurt, D6570r00001, D6570R00001, Germany
Research Site
Frankfurt/M., D6570r00001, D6570R00001, Germany
Research Site
Freiberg, D6570r00001, D6570R00001, Germany
Research Site
Fürstenwalde, D6570r00001, D6570R00001, Germany
Research Site
Fürth, D6570r00001, D6570R00001, Germany
Research Site
Ganderkesee, D6570r00001, D6570R00001, Germany
Research Site
Garching, D6570r00001, D6570R00001, Germany
Research Site
Garmisch-Partenkirchen, D6570r00001, D6570R00001, Germany
Research Site
Gauting, D6570r00001, D6570R00001, Germany
Research Site
Gera, D6570r00001, D6570R00001, Germany
Research Site
Gerwisch, D6570r00001, D6570R00001, Germany
Research Site
Glienicke, D6570r00001, D6570R00001, Germany
Research Site
Greiz, D6570r00001, D6570R00001, Germany
Research Site
Gütersloh, D6570r00001, D6570R00001, Germany
Research Site
Hagen, D6570r00001, D6570R00001, Germany
Research Site
Halberstadt, D6570r00001, D6570R00001, Germany
Research Site
Halle, D6570r00001, D6570R00001, Germany
Research Site
Hamburg, D6570r00001, D6570R00001, Germany
Research Site
Hanover, D6570r00001, D6570R00001, Germany
Research Site
Hartenstein, D6570r00001, D6570R00001, Germany
Research Site
Heidelberg, D6570r00001, D6570R00001, Germany
Research Site
Hemmingen, D6570r00001, D6570R00001, Germany
Research Site
Hettstedt, D6570r00001, D6570R00001, Germany
Research Site
Hoyerswerda, D6570r00001, D6570R00001, Germany
Research Site
Höchstadt an der Aisch, D6570r00001, D6570R00001, Germany
Research Site
Ibbenbueren, D6570r00001, D6570R00001, Germany
Research Site
Ingolstadt, D6570r00001, D6570R00001, Germany
Research Site
Iserlohn, D6570r00001, D6570R00001, Germany
Research Site
Issum, D6570r00001, D6570R00001, Germany
Research Site
Jena, D6570r00001, D6570R00001, Germany
Research Site
Karlsruhe, D6570r00001, D6570R00001, Germany
Research Site
Kevelaer, D6570r00001, D6570R00001, Germany
Research Site
Kleve, D6570r00001, D6570R00001, Germany
Research Site
Koeln-Hoehenberg, D6570r00001, D6570R00001, Germany
Research Site
Koeln-Rodenkirchen, D6570r00001, D6570R00001, Germany
Research Site
Kolbermoor, D6570r00001, D6570R00001, Germany
Research Site
Köthen, D6570r00001, D6570R00001, Germany
Research Site
Krefeld, D6570r00001, D6570R00001, Germany
Research Site
Kronach, D6570r00001, D6570R00001, Germany
Research Site
Kyritz, D6570r00001, D6570R00001, Germany
Research Site
Langenfeld, D6570r00001, D6570R00001, Germany
Research Site
Leer, D6570r00001, D6570R00001, Germany
Research Site
Leipzig, D6570r00001, D6570R00001, Germany
Research Site
Leonberg, D6570r00001, D6570R00001, Germany
Research Site
Lippstadt, D6570r00001, D6570R00001, Germany
Research Site
Ludwigsburg-Ossweil, D6570r00001, D6570R00001, Germany
Research Site
Ludwigshafen, D6570r00001, D6570R00001, Germany
Research Site
Lübeck, D6570r00001, D6570R00001, Germany
Research Site
Magdeburg, D6570r00001, D6570R00001, Germany
Research Site
Mainz, D6570r00001, D6570R00001, Germany
Research Site
Mannheim, D6570r00001, D6570R00001, Germany
Research Site
Marburg, D6570r00001, D6570R00001, Germany
Research Site
Markt Bibart, D6570r00001, D6570R00001, Germany
Research Site
Menden, D6570r00001, D6570R00001, Germany
Research Site
Merzig, D6570r00001, D6570R00001, Germany
Research Site
Moers, D6570r00001, D6570R00001, Germany
Research Site
Monheim, D6570r00001, D6570R00001, Germany
Research Site
Mosbach, D6570r00001, D6570R00001, Germany
Research Site
Mönchengladbach, D6570r00001, D6570R00001, Germany
Research Site
Mühlhausen, D6570r00001, D6570R00001, Germany
Research Site
München, D6570r00001, D6570R00001, Germany
Research Site
Neumarkt, D6570r00001, D6570R00001, Germany
Research Site
Neunkirchen, D6570r00001, D6570R00001, Germany
Research Site
Neuruppin, D6570r00001, D6570R00001, Germany
Research Site
Neusäß, D6570r00001, D6570R00001, Germany
Research Site
Neustadt/Aisch, D6570r00001, D6570R00001, Germany
Research Site
Neuwied, D6570r00001, D6570R00001, Germany
Research Site
Nuremberg, D6570r00001, D6570R00001, Germany
Research Site
Oettingen in Bayern, D6570r00001, D6570R00001, Germany
Research Site
Oschatz, D6570r00001, D6570R00001, Germany
Research Site
Oy-Mittelberg, D6570r00001, D6570R00001, Germany
Research Site
Pirmasens, D6570r00001, D6570R00001, Germany
Research Site
Potsdam, D6570r00001, D6570R00001, Germany
Research Site
Pulheim-Braunweiler, D6570r00001, D6570R00001, Germany
Research Site
Radebeul, D6570r00001, D6570R00001, Germany
Research Site
Rastatt, D6570r00001, D6570R00001, Germany
Research Site
Rathenow, D6570r00001, D6570R00001, Germany
Research Site
Recklinghausen, D6570r00001, D6570R00001, Germany
Research Site
Remscheid, D6570r00001, D6570R00001, Germany
Research Site
Reutlingen, D6570r00001, D6570R00001, Germany
Research Site
Rosenheim, D6570r00001, D6570R00001, Germany
Research Site
Rostock, D6570r00001, D6570R00001, Germany
Research Site
Roth, D6570r00001, D6570R00001, Germany
Research Site
Rust, D6570r00001, D6570R00001, Germany
Research Site
Rüdersdorf, D6570r00001, D6570R00001, Germany
Research Site
Rüsselsheim am Main, D6570r00001, D6570R00001, Germany
Research Site
Saalfeld, D6570r00001, D6570R00001, Germany
Research Site
Saarbrücken, D6570r00001, D6570R00001, Germany
Research Site
Saarlouis, D6570r00001, D6570R00001, Germany
Research Site
Schleswig, D6570r00001, D6570R00001, Germany
Research Site
Schmölln, D6570r00001, D6570R00001, Germany
Research Site
Schönbrunn, D6570r00001, D6570R00001, Germany
Research Site
Schwedt, D6570r00001, D6570R00001, Germany
Research Site
Siegen, D6570r00001, D6570R00001, Germany
Research Site
Simmern, D6570r00001, D6570R00001, Germany
Research Site
Solingen, D6570r00001, D6570R00001, Germany
Research Site
Sonsbeck, D6570r00001, D6570R00001, Germany
Research Site
Spiesen, D6570r00001, D6570R00001, Germany
Research Site
Spremberg, D6570r00001, D6570R00001, Germany
Research Site
Steinhagen, D6570r00001, D6570R00001, Germany
Research Site
Strausberg, D6570r00001, D6570R00001, Germany
Research Site
Straßkirchen, D6570r00001, D6570R00001, Germany
Research Site
Stuttgart, D6570r00001, D6570R00001, Germany
Research Site
Sulzberg, D6570r00001, D6570R00001, Germany
Research Site
Teterow, D6570r00001, D6570R00001, Germany
Research Site
Teuchern, D6570r00001, D6570R00001, Germany
Research Site
Thaleischweiler-Fröschen, D6570r00001, D6570R00001, Germany
Research Site
Trier, D6570r00001, D6570R00001, Germany
Research Site
Ulm, D6570r00001, D6570R00001, Germany
Research Site
Unterwellenborn, D6570r00001, D6570R00001, Germany
Research Site
Ursensollen, D6570r00001, D6570R00001, Germany
Research Site
Voerde, D6570r00001, D6570R00001, Germany
Research Site
Wallenhorst, D6570r00001, D6570R00001, Germany
Research Site
Wardenburg, D6570r00001, D6570R00001, Germany
Research Site
Waren, D6570r00001, D6570R00001, Germany
Research Site
Warendorf, D6570r00001, D6570R00001, Germany
Research Site
Wehrheim, D6570r00001, D6570R00001, Germany
Research Site
Weilheim, D6570r00001, D6570R00001, Germany
Research Site
Weißenburg, D6570r00001, D6570R00001, Germany
Research Site
Weißwasser, D6570r00001, D6570R00001, Germany
Research Site
Wiesbaden, D6570r00001, D6570R00001, Germany
Research Site
Witten, D6570r00001, D6570R00001, Germany
Research Site
Wittenberg, D6570r00001, D6570R00001, Germany
Research Site
Worms, D6570r00001, D6570R00001, Germany
Research Site
Wuppertal, D6570r00001, D6570R00001, Germany
Research Site
Zwönitz, D6570r00001, D6570R00001, Germany
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Target Duration
- 12 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 29, 2015
First Posted
September 17, 2015
Study Start
September 24, 2015
Primary Completion
December 31, 2017
Study Completion
December 31, 2017
Last Updated
December 11, 2018
Record last verified: 2018-12